Sort   by:  
 Page size 
UnknownSARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites.
Not available
S-EPMC9297724 | biostudies-literature
UnknownQuantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response.
Not available
S-EPMC9372021 | biostudies-literature
UnknownImmune boosting by B.1.1.529 <b>(</b>Omicron) depends on previous SARS-CoV-2 exposure.
Not available
S-EPMC9210451 | biostudies-literature
UnknownBlood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study.
Not available
S-EPMC8260104 | biostudies-literature
UnknownHLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.
Not available
S-EPMC9111350 | biostudies-literature
UnknownPre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Not available
S-EPMC8732273 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
UnknownCost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Not available
S-EPMC9896372 | biostudies-literature
UnknownAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Not available
S-EPMC9714135 | biostudies-literature
Sort   by:  
 Page size